Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TTLL5 (Tubulin polyglutamylase TTLL5) is an enzyme that catalyzes the polyglutamylation of tubulin, generating polyglutamate side chains essential for microtubule stability and function[1][6]. The protein preferentially modifies the C-terminal tail of α-tubulin and plays a central role in the function of cilia, especially in photoreceptor cells. TTLL5 acts both as an enzyme for tubulin posttranslational modification and as a transcriptional coregulator with nuclear receptors such as the glucocorticoid and androgen receptors[1][7]. TTLL5 is critical for proper photoreceptor cilium function, and loss-of-function or pathogenic missense mutations cause inherited retinal diseases, most notably cone-rod dystrophy type 19 (CORD19), a ciliopathy characterized by progressive vision loss due to cone and rod photoreceptor dysfunction[2][5]. Mutations in TTLL5 may also affect other cilia-dependent processes, such as sperm motility[5]. No small-molecule drugs or direct modulators are currently known to target TTLL5 directly in the clinic.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tubulin polyglutamylase TTLL5 (TTLL5).